You must have the latest Flash plugin to view this slideshow. 63-year history of research and clinical excellence

New targeted therapy effective in patients with drug-resistant metastatic gastrointestinal stromal tumor

June 04, 2012

Regorafenib was found to reduce the risk of disease progression or death by more than 70 percent in patients whose tumors had become resistant to Gleevec and Sutent.

New strategy directly activates cellular 'death protein'
May 31, 2012

Researchers at Dana-Farber/Children's Hospital Cancer Center have devised a strategy to directly activate a natural "death" protein, triggering the self-destruction of cells — which could lead to new possibilities for designing cancer drugs.

Study reports first success of targeted therapy in most common genetic subtype of non-small cell lung cancer
May 31, 2012

Dana-Farber researchers report a novel compound has become the first targeted therapy to benefit patients with non-small cell lung cancer.

New drug strategy attacks resistant leukemia and lymphoma
May 29, 2012

Researchers at Dana-Farber/Children's Hospital Cancer Center have created a peptide that overcomes drug resistance and reactivates programmed cell death in recurrent blood cancers.

Cancer survivors face a new challenge in care (ABC News.com)

May 17, 2012

Dr. Ann Partridge discusses new efforts for improved survivorship care. Catherine Fitch, a former Dana-Farber patient, provides insight into the challenges she has faced in the 36 years since surviving Hodgkin's lymphoma.

J&J’s Zytiga helps eliminate early-stage prostate cancer (Bloomberg News)
May 17, 2012

A study led by Dr. Mary Ellen Taplin that looked at small group of men with prostate cancer showed that treatment with Zytiga eliminated or greatly reduced the size of prostate tumors in one-third of patients treated for six months before surgery.

Patriots' Devin McCourty hits the hospital to see patients (Boston Globe)
May 17, 2012

Patriots players Devin McCourty and Julian Edelman visited patients and signed autographs at the Kraft Family Blood Donor Center at Dana-Farber as part of the Patriots Charitable Foundation’s Celebrate Volunteerism campaign.

Insight: Training immune system to fight cancer comes of age (Reuters)
May 07, 2012

Dr. Glenn Dranoff talks about the new era of immune therapies being recognized as an important component of cancer treatment.

Jimmy Fund Scooper Bowl®

June 05, 2012

12:00 AM - 12:00 AM

City Hall Plaza, Boston

Please join us for the 30th annual all-you-can-eat ice cream festival at Boston City Hall Plaza. The event runs from noon to 8:00 p.m. more

Burger King - A Chance for Kids®

June 04, 2012

Participating Restaurants

Burger King - A Chance for Kids® more

Stop & Shop Triple Winner Program

June 04, 2012

April 13 through July 12, Stop & Shop customers have the opportunity to help support pediatric brain tumor care and research at Dana-Farber Cancer Institute through Stop & Shop's annual Triple Winner Game®. Customers who give a $1 contribution to the Jimmy Fund receive a Triple Winner Game card and receive free store products, coupons, gift cards, or cash prizes up to $10,000.

Stop & Shop Triple Winner Program 

more

Thriving with Yoga

June 04, 2012

4:30 PM - 5:30 PM

Elliott Regional Cancer Center 40 Buttrick Rd Londonderry NH

A free program in partnership with YogaCaps, Inc. Open to beginners and those experienced with yoga with a current or past cancer diagnosis. Please call 603-670-0302 to register. more

  •  
  • Patient referral information, clinical resources and more.

  • Request an Appointment


    For adults:
    877-442-3324 (877-442-DFCI)

    For children:
    888-733-4662 (888-PEDI-ONC)

    Or complete the online form.

  • Clinical Trials

    Search current cancer clinical trials at Dana-Farber.

  • How to Help

    Yawkey Center for Cancer Care entrance 

    There are many ways to support Dana-Farber and the Jimmy Fund.

    give now button
  • Dana-Farber Blog

    Insight Blog screenshot

    Insight features the latest in cancer care and research news from Dana-Farber.
    Read the blog